Targeting islet G-protein-coupled receptors for type 2 diabetes therapy

Shanta J. Persaud*, Oladapo E. Olaniru, Patricio Atanes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The majority of people with diabetes have type 2 diabetes (T2D), where hyperglycaemia occurs because the islet p-cells are unable to secrete enough insulin, usually in the context of insulin resistance that arises because of fat mass expansion. There are a range of pharmacotherapies in current use to treat T2D and pharmaceutical companies are actively engaged in the development of novel therapies for better glucose control. Ligands that target G-protein-coupled receptors (GPCRs) are obvious candidates because they are used successfully for a wide range of disorders and GLP-1 receptor agonists, which are a relatively recent class of diabetes therapy, have proved to be very effective in treating T2D. We provide here an overview of current successes, some drawbacks and future possibilities for GPCR-based T2D therapies.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
Issue number2
Publication statusPublished - 2021


Dive into the research topics of 'Targeting islet G-protein-coupled receptors for type 2 diabetes therapy'. Together they form a unique fingerprint.

Cite this